Medical Doctor Program year 2025 Reported 2023–2025 Source: CMS Open Payments, 2026 publication

Jospeph Scalea

Transplant Surgery Baltimore, MD Medical Doctor

NPI 1144423112 CMS profile 1249693

22 S Greene St, Baltimore, MD 21201

Open in the dashboard

General payments

$7,779

12 records reported · program years 2023–2025

Research payments

$0

Paid to them · None reported · program years 2023–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jospeph Scalea of Baltimore, MD is reported in the CMS Open Payments database as having received $7,779 across 12 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 75th percentile of Transplant Surgery profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

3 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $3,100 1
2024 General $22 1
2023 General $4,658 10

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jospeph Scalea
  • Transplant Surgery median
  • Middle half of Transplant Surgery
  • National median

In program year 2025, general payments to Jospeph Scalea were reported at $3,100. Among 555 Transplant Surgery profiles paid that year, the median was $421 and the middle half received between $116 and $2,169.

Show as a table
Year Jospeph Scalea Transplant Surgery median Middle half National median
2019 $0 $203 $77–$1,249 $163
2020 $0 $149 $52–$1,366 $114
2021 $0 $168 $73–$2,008 $132
2022 $0 $213 $94–$1,464 $149
2023 $4,658 $262 $93–$1,458 $160
2024 $22 $354 $126–$2,252 $164
2025 $3,100 $421 $116–$2,169 $169

Breakdown

Who paid General payments · program years 2023–2025
  1. Sanofi-Aventis U.S. LLC $3,798 1 payment
  2. Vertex Pharmaceuticals Incorporated $3,100 1 payment
  3. Intuitive Surgical, Inc. $706 7 payments
  4. OrganOx Ltd $154 2 payments
  5. Medtronic, Inc. $22 1 payment

Every payment, record by record

What the payments were for General payments · program years 2023–2025
  1. Consulting Fee $6,898 2 payments
  2. Travel and Lodging $677 6 payments
  3. Food and Beverage $205 4 payments
Products named General payments · program years 2023–2025
  1. THYMOGLOBULIN $3,798 1 payment
  2. Da Vinci Surgical System $706 7 payments
  3. METRA $154 2 payments
  4. AQUAMANTYS(TM) $22 1 payment

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 26 drugs

Part D claims

848

Median for General Surgery: 59

Drug cost

$254,213

Median for General Surgery: $393

Branded share of claims

23.3%

Median for General Surgery: 28.9%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Mavyret Glecaprevir/Pibrentasvir Brand 15 $162,691
Valganciclovir Hcl Generic 102 $34,287
Envarsus Xr Tacrolimus Brand 18 $28,710
Eliquis Apixaban Brand 12 $10,323
Atovaquone Generic 16 $9,613
Mycophenolate Mofetil Generic 25 $2,028
Sevelamer Carbonate Generic 15 $1,139
Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim Brand 119 $965
Pantoprazole Sodium Generic 27 $729
Famotidine Generic 78 $713

The 10 drugs with the highest cost, of 26 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 15,891 Part D prescribers listed as General Surgery; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 29 billing codes

Paid by Medicare

$81,477

Medicare's payments for the services billed

Medicare patients

122

Average age 55

Services billed

367

43 women, 79 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Chronic kidney disease 75%
Diabetes 64%
Heart failure 47%
Ischemic heart disease 39%
Arthritis 30%
Atrial fibrillation 23%
Depression 23%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

12 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Transplant Surgery in Maryland

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record